secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2024-11-26T23:59:59+00:00
Accession:  0000950170-24-130763
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo's Peter Pavlik to present ADAPTIR platform at Pep Talk; new molecule expected in early 2025
--------------------------------------------------------------------------------

- Peter Pavlik, PhD, will chair a 'Bi and Multispecific Biologics' session at Pep Talk conference in January 2025.
- Presentation will highlight ADAPTIR platform using clinical candidates Mipletamig and ALG.APV-527 as proof of concept.
- Aptevo has five compounds in clinical/preclinical development and plans a new molecule in early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024130763/0000950170-24-130763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024130763/apvo-20241126.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-130763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer